NYSE:AORT

Artivion (AORT) Stock Forecast, Price & News

$15.45

+0.50 (+3.34%)

(As of 06/6/2023 ET)

Compare

Today's Range: $14.88
▼
$15.46
50-Day Range: $12.39
▼
$15.45
52-Week Range: $9.64
▼
$23.43

Volume: 170,415 shs
Average Volume: 142,300 shs
Market Capitalization: $631.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.50

Artivion MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 45.6% Upside
$22.50 Price Target
Short Interest: Bearish
7.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.11) to $0.19 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

633rd out of 981 stocks

Surgical & Medical Instruments Industry

61st out of 97 stocks

3.4

Analyst's Opinion

Consensus Rating
Artivion has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.50, Artivion has a forecasted upside of 45.6% from its current price of $15.45.
Amount of Analyst Coverage
Artivion has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.89% of the float of Artivion has been sold short.
Short Interest Ratio / Days to Cover
Artivion has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Artivion has recently decreased by 0.32%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Artivion does not currently pay a dividend.
Dividend Growth
Artivion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AORT.

0.6

News and Social Media Coverage

MarketBeat Follows
2 people have added Artivion to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Artivion insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Artivion is held by insiders.
Percentage Held by Institutions
87.99% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Artivion are expected to grow in the coming year, from ($0.11) to $0.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Artivion is -21.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Artivion is -21.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Artivion has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Artivion (NYSE:AORT) Stock

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

AORT Stock News Headlines

May 26, 2023 | americanbankingnews.com

Artivion (NYSE:AORT) versus ProSomnus (NASDAQ:OSA) Head-To-Head Comparison

May 24, 2023 | americanbankingnews.com

Analyzing Artivion (NYSE:AORT) and PAVmed (NASDAQ:PAVM)

June 6, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 23, 2023 | markets.businessinsider.com

Artivion To Receive Milestone Payment From Baxter On FDA PMA Approval For PerClot

May 23, 2023 | msn.com

Artivion wins FDA nod for Baxter-partnered clotting product

May 17, 2023 | americanbankingnews.com

Critical Contrast: Artivion (NYSE:AORT) vs. Baxter International (NYSE:BAX)

May 8, 2023 | msn.com

Morgan Stanley Maintains Artivion (AORT) Equal-Weight Recommendation

May 5, 2023 | msn.com

Needham Maintains Artivion (AORT) Buy Recommendation

June 6, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 4, 2023 | msn.com

Artivion: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Artivion (AORT) Q1 Earnings and Revenues Beat Estimates

May 4, 2023 | finance.yahoo.com

Artivion Reports First Quarter 2023 Financial Results

May 4, 2023 | americanbankingnews.com

Head-To-Head Contrast: Nyxoah (NASDAQ:NYXH) vs. Artivion (NYSE:AORT)

May 3, 2023 | americanbankingnews.com

Artivion (AORT) Scheduled to Post Earnings on Thursday

April 22, 2023 | benzinga.com

Artivion Stock (NYSE:AORT), Dividends

April 20, 2023 | finance.yahoo.com

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results

April 20, 2023 | seekingalpha.com

Artivion: Reaffirm Hold As Pressures To Growth Remain

April 12, 2023 | americanbankingnews.com

Artivion (NYSE:AORT) versus iRhythm Technologies (NASDAQ:IRTC) Financial Contrast

April 10, 2023 | finance.yahoo.com

Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference

March 31, 2023 | finance.yahoo.com

Shareholders in Artivion (NYSE:AORT) are in the red if they invested a year ago

March 6, 2023 | finance.yahoo.com

Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference

March 2, 2023 | benzinga.com

Massive Insider Trade At Artivion

February 18, 2023 | yahoo.com

The Returns On Capital At Artivion (NYSE:AORT) Don't Inspire Confidence

February 17, 2023 | fool.com

Why Artivion Stock Popped Today

February 17, 2023 | finanznachrichten.de

Artivion, Inc.: Artivion Reports Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023 | apnews.com

Artivion: Q4 Earnings Snapshot

February 16, 2023 | msn.com

Artivion (AORT) Q4 Earnings Surpass Estimates

See More Headlines

AORT Price History

30 days | 90 days | 365 days | Advanced Chart

AORT Company Calendar

Last Earnings: 2/17/2022
Today: 6/06/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:AORT
CUSIP: N/A
CIK: 784199
Web: www.cryolife.com
Phone: (770) 419-3355
Fax: 770-426-0031
Employees: 1,300
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.50
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +47.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,190,000.00
Net Margins: -9.17%
Pretax Margin: -6.71%
Return on Equity: 0.65%
Return on Assets: 0.24%

Debt

Debt-to-Equity Ratio: 1.11
Current Ratio: 5.47
Quick Ratio: 3.74

Sales & Book Value

Annual Sales: $313.79 million
Price / Sales: 1.99
Cash Flow: $0.61 per share
Price / Cash Flow: 25.16
Book Value: $7.05 per share
Price / Book: 2.17

Miscellaneous

Outstanding Shares: 40,880,000
Free Float: 38,177,000
Market Cap: $624.24 million
Optionable: Optionable
Beta: 1.39

Key Executives

James Patrick Mackin
Chairman, President & Chief Executive Officer

David Ashley Lee
Chief Financial & Operating Officer, EVP

Scott B. Capps
Vice President-Clinical Research

Franz Peter Barthold
Vice President-Research & Development

Marshall S. Stanton
Chief Medical Officer & SVP-Clinical Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AORT Stock - Frequently Asked Questions

Should I buy or sell Artivion stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AORT shares.
View AORT analyst ratings or view top-rated stocks.
What is Artivion's stock price forecast for 2023?: 4 brokers have issued twelve-month price objectives for Artivion's stock. Their AORT share price forecasts range from $14.00 to $28.00. On average, they expect the company's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price.
View analysts price targets for AORT or view top-rated stocks among Wall Street analysts.
How have AORT shares performed in 2023?: Artivion's stock was trading at $12.12 at the beginning of 2023. Since then, AORT stock has increased by 26.0% and is now trading at $15.27.
View the best growth stocks for 2023 here.
When is Artivion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AORT earnings forecast.
How were Artivion's earnings last quarter?: Artivion, Inc. (NYSE:AORT) posted its quarterly earnings results on Thursday, February, 17th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.45. The company had revenue of $79.39 million for the quarter, compared to the consensus estimate of $78 million. Artivion had a negative net margin of 9.17% and a positive trailing twelve-month return on equity of 0.65%.
What ETFs hold Artivion's stock?: ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Inspire Small/Mid Cap ETF (ISMD), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI),

What guidance has Artivion issued on next quarter's earnings?: Artivion issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $337.00 million-$348.00 million, compared to the consensus revenue estimate of $337.66 million.
What is Artivion's stock symbol?: Artivion trades on the New York Stock Exchange (NYSE) under the ticker symbol "AORT."
Who are Artivion's major shareholders?: Artivion's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (17.23%), Macquarie Group Ltd. (6.68%), Macquarie Group Ltd. (6.68%), Wellington Management Group LLP (5.86%), State Street Corp (3.94%) and Dimensional Fund Advisors LP (3.33%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin and Rochelle L Maney.
View institutional ownership trends.
How do I buy shares of Artivion?: Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Artivion's stock price today?: One share of AORT stock can currently be purchased for approximately $15.27.
How much money does Artivion make?: Artivion (NYSE:AORT) has a market capitalization of $624.24 million and generates $313.79 million in revenue each year. The company earns $-19,190,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.
How many employees does Artivion have?: The company employs 1,300 workers across the globe.
How can I contact Artivion?: Artivion's mailing address is 1655 Roberts Blvd NW, Kennesaw, Georgia 30144-3632. The official website for the company is www.cryolife.com. The company can be reached via phone at (770) 419-3355, via email at investors@cryolife.com, or via fax at 770-426-0031.

This page (NYSE:AORT) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial